Active Recombinant Human BACE1 protein, His-tagged

• Cat.No.: BACE1-2940H
• Product Overview: Recombinant Human BACE1 protein(Thr 22-Thr 457), fused with His tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: His
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
• Bio-activity: Measured by its ability to cleave a fluorogenic peptide substrate, Mca-SEVNLDAEFRK(Dpn)RR-NH2. The specific activity is >2.5 pmol/min/µg, as measured under the described conditions.
• Molecular Mass: This protein carries a polyhistidine tag at the C-terminusThe protein has a calculated MW of 49.3 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Protein length: Thr 22-Thr 457
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >95% as determined by SDS-PAGE. >95% as determined by SEC-MALS.
• Storage: For long term storage, the product should be stored at lyophilized state at-20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after storage at:-20°C to-70°C for 12 months in lyophilized state;-70°C for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: BACE1 beta-site APP-cleaving enzyme 1 [ Homo sapiens ]
• Official Symbol: BACE1
• Synonyms: BACE1; beta-site APP-cleaving enzyme 1; BACE, beta site APP cleaving enzyme; beta-secretase 1; asp 2; memapsin-2; APP beta-secretase; aspartyl protease 2; beta-site APP cleaving enzyme 1; beta-secretase 1 precursor variant 1; transmembrane aspartic proteinase Asp2; membrane-associated aspartic protease 2; beta-site amyloid beta A4 precursor protein-cleaving enzyme; ASP2; BACE; HSPC104; FLJ90568; KIAA1149
• Gene ID: 23621
• mRNA Refseq: NM_001207048
• Protein Refseq: NP_001193977
• MIM: 604252
• UniProt ID: P56817

Reviews

07/27/2020

Such support ensures researchers have access to reliable tools and expertise, facilitating their investigations into the functions, mechanisms, and disease relevance of BACE1 protein.

12/23/2019

A manufacturer can serve as a collaborative partner, engaging in discussions, and exchanging knowledge with researchers.

09/30/2019

Using BACE1 protein in trials provides advantages such as its involvement in cellular processes and its disease associations.

Q&As

Are there any potential side effects associated with BACE1 inhibition?

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

How is BACE1 linked to Alzheimer's disease?

BACE1 is implicated in Alzheimer's disease as it initiates the cleavage of APP, leading to the formation of beta-amyloid plaques, a hallmark of the disease.

How can BACE1 inhibitors potentially benefit Alzheimer's patients?

BACE1 inhibitors may slow down or prevent the accumulation of beta-amyloid plaques, potentially delaying the progression of Alzheimer's disease.

Are there any ongoing clinical trials involving BACE1 inhibitors?

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

Are there clinical applications of BACE1 inhibitors?

Yes, BACE1 inhibitors are being explored as potential therapeutic agents for Alzheimer's disease to reduce the production of beta-amyloid peptides.